-
AD/PD 2025: Cerevance’s Solengepras falls short of primary endpoint in ASCEND trial
03 Apr 2025 21:32 GMT
… for the treatment of core PD symptoms, such as levodopa, dopamine … marketed across the seven major pharmaceutical markets (7MM: US, France, … large Phase III clinical trials or engage in head- … ASCEND trial as a monotherapy for early PD, the drug demonstrated …
-
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
03 Apr 2025 12:35 GMT
… levodopa) extended-release capsules is a prescription medication for the treatment … not take CREXONT with antidepressant medications known as nonselective … Have side effects; your doctor can adjust your dose. … Pharmaceuticals, LLC at 1-877-835-5472 or the FDA …
-
Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setback
02 Apr 2025 19:46 GMT
… Parts II+III.
The biotech said the data is not … treatment arm completing the 12-week trial and no discontinuations due to drug … and assistant professor of medicine at Oakland University William … therapy with levodopa in another Phase II trial (NCT04191577) …
-
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
01 Apr 2025 12:15 GMT
… 12-week trial and no discontinuations due to a study-drug related … therapy to levodopa and other background Parkinson’s disease medications. The trial is … progresses. Our most advanced investigational treatment, solengepras, is currently in Phase …
-
Parkinson's Disease Market Outlook 2025-2034: Growth Drivers, Key Segments, Market Share, and Emerging Trends
27 Mar 2025 14:45 GMT
… funding, personalized treatment plans, supportive networks … solutions, and personalized medicine will also greatly … 47;S, Takeda Pharmaceutical Company Limited, UCB … Drug Administration FDA approval for VYALEV, a combination therapy containing levodopa …
-
AD/PD 2025: Roche highlights time-to-event for assessing prasinezumab in early PD
03 Apr 2025 21:31 GMT
… early PD on stable symptomatic treatment (PADOVA). The presentation … 2025 ‘Advances in PD Treatment’ presentation, Roche announced that … the patients who received levodopa therapy, which accounted for … .
The current medications used for the treatment of PD are …
-
Levodopa Shows Promise in Treating Depression with Inflammation-Related Motivational Impairments
21 Mar 2025 10:18 GMT
… University suggests that levodopa, a medication that increases … well to standard antidepressants,” says principal investigator … treatment of depression,” Felger says.
A follow-up randomized clinical trial … clarify levodopa’s potential as a targeted treatment …
-
Patient-Informed Phase 2 ATLANTIS Study Tests Selective D1PAM Agent Glovadalen for Parkinson Disease
03 Apr 2025 12:39 GMT
… controlled, randomized, parallel-group trial, includes 207 patients across 69 … Milton Biagioni, MD, senior medical director of UCB’s … treatment to standard of care, which includes at least levodopa … models, and early clinical trials suggest they could offer …
-
Human medicines European public assessment report (EPAR): Rasagiline ratiopharm, rasagiline, Date of authorisation: 12/01/2015, Revision: 9, Status: Authorised
20 Mar 2025 00:47 GMT
… the studies, a 26-week treatment with Rasagiline ratiopharm resulted in … treated with levodopa, and compared with placebo and another medicine entacapone (also …
-
Levodopa may improve motivation in depression linked to high inflammation
20 Mar 2025 03:24 GMT
… University suggests that levodopa, a medication that increases … well to standard antidepressants,” says principal investigator … treatment of depression,” Felger says.
A follow-up randomized clinical trial … clarify levodopa’s potential as a targeted treatment …